Company intelligence / Profile preview

Pendiq Intelligent Diabetes Care

Germany

Ownership: Private
Development stage: Other

Overview

Pendiq 2.0 is a Bluetooth-enabled smart insulin pen allowing highly precise, motor-driven dosing (increments of 0.1 units), data logging of up to 1,000 entries (time, dose) viewable on OLED display, with USB charging, safety alarms, and app integration. Compatible with rapid-acting insulin cartridges. Device is commercialized in Germany. No direct clinical trial results cited; performance is supported by inclusion in market reports and device reviews

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Pendiq Intelligent Diabetes Care.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pendiq Intelligent Diabetes Care.

Explore the full profile